BR9801808A - Quinazolin-4-ona como antagonista do ampa. - Google Patents

Quinazolin-4-ona como antagonista do ampa.

Info

Publication number
BR9801808A
BR9801808A BR9801808A BR9801808A BR9801808A BR 9801808 A BR9801808 A BR 9801808A BR 9801808 A BR9801808 A BR 9801808A BR 9801808 A BR9801808 A BR 9801808A BR 9801808 A BR9801808 A BR 9801808A
Authority
BR
Brazil
Prior art keywords
optionally substituted
fluorine atoms
halo
cyano
alkyl
Prior art date
Application number
BR9801808A
Other languages
English (en)
Inventor
Bertrand Leo Chenard
Anthony Ronald Reinhold
Willard Mckowan Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9801808A publication Critical patent/BR9801808A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Patente de Invenção; <B>"QUINAZOLIN-4-ONA COMO ANTAGONISTAS DO AMPA"<D> A presente invenção refere-se a novos derivados da quinazolin-4-ona da fórmula farmacêuticas contendo esses compostos, e o uso de tais compostos para tratar distúrbios do sistema nervoso central e periférico neurodegenerativos,
BR9801808A 1997-06-09 1998-06-09 Quinazolin-4-ona como antagonista do ampa. BR9801808A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4908297P 1997-06-09 1997-06-09
US5327497P 1997-07-21 1997-07-21

Publications (1)

Publication Number Publication Date
BR9801808A true BR9801808A (pt) 2000-03-21

Family

ID=26726849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9801808A BR9801808A (pt) 1997-06-09 1998-06-09 Quinazolin-4-ona como antagonista do ampa.

Country Status (7)

Country Link
EP (1) EP0884310B1 (pt)
JP (1) JP3415443B2 (pt)
AT (1) ATE303997T1 (pt)
BR (1) BR9801808A (pt)
CA (1) CA2240138C (pt)
DE (1) DE69831446T2 (pt)
ES (1) ES2245015T3 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
KR20020062930A (ko) * 1999-10-27 2002-07-31 싸이토키네틱스, 인코포레이티드 퀴나졸리논을 사용하는 방법 및 조성물
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
EP1446407A2 (en) * 2001-06-14 2004-08-18 Akzo Nobel N.V. (pyrido/thieno)-(f)-oxazepin-5-one derivatives as positive modulators of the ampa receptor
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
ATE372341T1 (de) * 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2607929A1 (en) * 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
ITRM20060491A1 (it) * 2006-09-15 2008-03-16 Giuseppe Campiani Composti attivi sui recetori glutammatergici
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2975473C (en) 2008-11-13 2021-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
AU2010239312A1 (en) 2009-04-20 2011-11-10 Gilead Calistoga Llc Methods of treatment for solid tumors
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
AU2012284091B2 (en) * 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN104334560A (zh) 2012-03-05 2015-02-04 吉利德卡利斯托加有限责任公司 (s)-2-(1-(9h-嘌呤-6-基氨基)丙基)-5-氟-3-苯基喹唑啉-4(3h)-酮的多晶型物
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
PT2941426T (pt) 2012-12-21 2018-07-18 Gilead Calistoga Llc Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
EP3008053B1 (en) 2013-06-14 2018-03-21 Gilead Calistoga LLC Phosphatidylinositol 3-kinase inhibitors
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
IL310023A (en) 2017-06-21 2024-03-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128136T1 (de) * 1990-05-31 1995-10-15 Merck Sharp & Dohme Dioxo-tetrahydrochinolinderivate.
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
DE69831446D1 (de) 2005-10-13
ES2245015T3 (es) 2005-12-16
EP0884310A1 (en) 1998-12-16
DE69831446T2 (de) 2006-06-14
CA2240138A1 (en) 1998-12-09
CA2240138C (en) 2002-08-20
EP0884310B1 (en) 2005-09-07
ATE303997T1 (de) 2005-09-15
JPH1112255A (ja) 1999-01-19
JP3415443B2 (ja) 2003-06-09

Similar Documents

Publication Publication Date Title
BR9801808A (pt) Quinazolin-4-ona como antagonista do ampa.
YU59602A (sh) Aril fuzionisana azapoliciklična jedinjenja
ATE234299T1 (de) Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
MY118163A (en) Aryl fused azapolycyclic compounds
WO2006046031A8 (en) Pharmaceutical compounds
CA2239705A1 (en) Quinazoline-4-one ampa antagonists
ATE339409T1 (de) Trizyklische verbindungen
BR0006333A (pt) Compostos heteroaril-fenil-pirazol como agentesantiinflamatórios e analgésicos
YU64400A (sh) Aril fuzirana azapoliciklična jedinjenja
NZ536524A (en) Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
HK1018782A1 (en) 2,3-benzodiazepine derivatives their preparation as well as the intermediates and their use as medicaments
DE60013716D1 (de) Tetrahydrochinazolin-2,4-dione zur Verwendung als therapeutische Medikamente
PT1178047E (pt) Derivados diazabiciclooctano e seus usos terapeuticos
UY26147A1 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
BRPI0412880A (pt) compostos azapolicìclicos fundidos a arila
EP0919233B8 (en) Therapeutic agent for kidney diseases

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36O DA LPI